The House coronavirus subcommittee has asked the Government Accountability Office (GAO) to begin a review of the Trump administration’s Operation Warp Speed initiative. Read More

Maryland-based Emergent BioSolutions has secured a $174 million contract with AstraZeneca (AZ) for large-scale manufacturing of drug substances for the UK company’s COVID-19 vaccine. Read More

Pfizer and BioNTech began a phase 2/3 trial yesterday of one of their COVID-19 vaccine candidates, but not the one originally considered to be the most promising. Read More

Moderna has begun a much-anticipated phase 3 trial of its COVID-19 vaccine candidate mRNA-1273 — the first phase 3 trial of a coronavirus vaccine in the U.S. Read More

The Patent Trial and Appeals Board (PTAB) has dismissed claims by Moderna that a Canadian rival’s patent on lipid nanoparticle (LNP) technology is invalid, in a ruling that could have implications for Moderna’s COVID-19 vaccine candidate mRNA-1273. Read More

Maryland-based Novavax has signed an agreement with Fujifilm Diosynth Biotechnologies to manufacture the bulk drug substance for Novavax’s COVID-19 vaccine candidate NVX-CoV2373. Read More

The Department of Justice (DOJ) said yesterday it will not stand in the way of pharmaceutical companies sharing information on the manufacturing of monoclonal antibodies for the treatment of COVID-19 patients. Read More